Article

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

Related Videos
Edgardo S. Santos, MD, FACP
Julie Renee Brahmer, MD
Sarah Sammons, MD
Laura Spring, MD
Laura Spring, MD
Corey J. Langer, MD
John F. Lazar, MD
Rodolfo Bordoni, MD
Related Content
An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer
April 11th 2024

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer
April 21st 2023

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

BTK Inhibitors in MCL and CLL
March 10th 2023

BTK Inhibitors in MCL and CLL

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?
January 25th 2023

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer
January 25th 2023

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
December 22nd 2022

Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma